Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Modified Preloaded System for Renal Arteries in Fenestrated Endografting (MPSRA) (MPSRA)

4 de febrero de 2022 actualizado por: Enrico Gallitto, University of Bologna

Modified Preloaded System for Renal Arteries in Fenestrated Endografting

Advanced Endovascular repair of aneurysms and dissections involving thoraco-abdominal (type I-IV) and complex abdominal (juxta and para-renal) aorta is a ground-gaining procedure allowing favorable results in high surgical risk patients. The availability of iliac vessels navigation and the major role of lower leg perfusion in order to decrease the risk of spinal cord ischemia during these complex procedures, led to the development of devices with lower sheaths sizes and to the improvement of the technique with preloaded devices for visceral vessels in order to navigate in hostile anatomies or when an iliac access is not available. The aim of the study is to evaluate in a prospective single center observational setting, the outcomes, safety and efficacy of the modified preloaded system for renal arteries in fenestrated endografting in the routine treatment of paravisceral and thoraco-abdominal aortic pathologies.

Descripción general del estudio

Descripción detallada

Thoracoabdominal aortic aneurysm (TAAA) and complex abdominal aortic aneurysms (AAA) represents an evolving pathology that involves to varying degrees both the descending thoracic aorta and the abdominal aorta. These aneurysms, according to their localization and involvement in the thoracic and abdominal aorta, have been classified according to Crawford into 4 groups (I-IV) for the TAAA and in pararenal/juxtarenal (p/j-AAA) for AAA when a standard endovascular repair is not possible.

The prevalence of these pathologies is currently not well known, but high mortality rates are reported in the population carrying TAAAs and j/p-AAAs that have not undergone surgical treatment, most of which are due to aortic rupture.

Among of the main complications related to TAAA endovascular repair and to complex AAA we can account spinal cord ischemia, lower leg ischemia and logo-operative times, that all can contribute to decrease overall technical and clinical success.

A particular subgroup of TAAAs is represented by post-dissection thoracoabdominal aneurysms (PDTAA), which represents an evolving pathology and one of the main chronic complications in outcomes of acute chronic dissection. In these particular subset of patients, as well as in patient with highly calcified and hostile accesses, the risk of post-operative spinal cord ischemia is higher and the availability of both iliac access navigability is not always possible, leading to technical failure, intraoperative complications and need for adjunctive invasive procedures in high surgical risk patients.

The fenestrated and branched endoprostheses (F/B-EVAR) represent a technology that is now firmly used for the treatment of thoraco-abdominal degenerative aneurysmal pathology in superspecialized centers. Recently, the technology with F/B-EVAR has also been used in the treatment of PDTAA, IMH and PAU, showing satisfactory results. This experience has been carried out in some centers, in the absence, however, of a wider and generalized experience. All these type of endografts are custom-made devices, requiring therefore a lading time for production and delivering before being implanted into the specific patient.

In order to overcome main drawbacks of these procedures, such us long operating time due to fenestrations and vessels cannulation, to avoid bilateral lower limbs ischemia due to large bore introducer sheaths and to accomplish successful delivery even in patient without navigability of both iliac accesses, a modified preloaded system for renal arteries has been developed by Cook (Cook Medical, Bloomington, IN, USA).

The aim of the study is to evaluate in a prospective single center study observational setting, the outcomes, safety and efficacy of the modified preloaded system for renal arteries developed by Cook Medical with bi-port handle system in the field of fenestrated endografting during the routine treatment of thoraco-abdominal and paravisceral abdominal aortic pathologies.

Tipo de estudio

De observación

Inscripción (Anticipado)

35

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Emilia Romagna
      • Bologna, Emilia Romagna, Italia, 40138
        • Reclutamiento
        • University of Bologna
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 100 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

All elective patients treated in a single center institution, with the standard of care for thoraco-abdominal and para-juxta-renal abdominal aortic aneurysms using fenestrated/branched custom-made endograft developed by Cook Medical with modified preloaded system for renal arteries.

Descripción

Inclusion Criteria:

  • Diagnosis of thoraco-abdominal or complex abdominal aortic aneurysm confirmed by a Computed tomography Angiography (CTA).
  • Etiologies will be degenerative aneurysms, inflammatory aneurysms, chronic post-dissectional aneurysms, penetrating aortic ulcers, failure of prior surgical or endovascular repair.
  • Elective aneurysmal repair of patient with maximum diameter greater than 55 mm, or fast growing, or symptomatic aneurysms.
  • Endovascular repair performed using custom-made fenestrated and/or branched endografting with presence of modified preloaded system with modified handle and preloaded catheters for visceral vessels cannulation.

Exclusion Criteria:

  • Patients submitted to advanced fenestrated and branched endovascular repair with other grafts besides the Cook Medical custom-made endograft or without modified handle preloaded delivery system.
  • Physician-modified devices
  • Patient treated with hybrid and/or open technique as well as parallel grafts (such as chimney/snorkel/periscope)
  • Patient treated as emergent/urgent patients or aneurysmal rupture
  • Patient who can not wait for the lead time required for endograft production and delivery.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Technical Success
Periodo de tiempo: Intra-operative final completion angiography.
Successful deployment of custom-made modified endograft, target vessel patency and aneurysm exclusion, in absence of intra-operative mortality.
Intra-operative final completion angiography.
Mortality
Periodo de tiempo: Within the first 30-days from the procedure.
Assessment of mortality related to procedure
Within the first 30-days from the procedure.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Cardiovascular Adverse Events
Periodo de tiempo: Within the first 30-days from the procedure.
Cardiopulmonary and renal events related to the procedure.
Within the first 30-days from the procedure.
Neurologic Adverse Events
Periodo de tiempo: Within the first 30-days from the procedure.
Incidence of Spinal Cord Ischemia (transient/permanent) and Stroke
Within the first 30-days from the procedure.
Vessel Instability
Periodo de tiempo: Within the first 30-days from the procedure.
Target vessel patency and absence of stenosis, endoleak, occlusion, need for reintervention
Within the first 30-days from the procedure.
Rate of early reintervention
Periodo de tiempo: Within the first 30-days from the procedure.
Any re-intervention needed after the type of procedure and the specific reason
Within the first 30-days from the procedure.
Overall Survival
Periodo de tiempo: Through study completion, an average of 1 year.
Assessment of mortality in the post-operative period
Through study completion, an average of 1 year.
Aorta Related Survival
Periodo de tiempo: Through study completion, an average of 1 year.
Assessment of mortality in the post-operative period related to aortic procedure or aortic related death.
Through study completion, an average of 1 year.
Freedom from reintervention
Periodo de tiempo: Through study completion, an average of 1 year.
Time from procedure to the first aortic related/procedure related reintervention
Through study completion, an average of 1 year.
Freedom from Vessel Instability
Periodo de tiempo: Through study completion, an average of 1 year.
Target vessel patency and absence of stenosis, endoleak, occlusion, need for reintervention
Through study completion, an average of 1 year.
Freedom from Major Endoleaks
Periodo de tiempo: Through study completion, an average of 1 year.
Time from procedure to the presence of high-flow endoleak (TypeI/III) and from endoleak that required reintervention
Through study completion, an average of 1 year.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de enero de 2019

Finalización primaria (Anticipado)

1 de junio de 2022

Finalización del estudio (Anticipado)

1 de diciembre de 2022

Fechas de registro del estudio

Enviado por primera vez

4 de enero de 2022

Primero enviado que cumplió con los criterios de control de calidad

24 de enero de 2022

Publicado por primera vez (Actual)

4 de febrero de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

22 de febrero de 2022

Última actualización enviada que cumplió con los criterios de control de calidad

4 de febrero de 2022

Última verificación

1 de febrero de 2022

Más información

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

3
Suscribir